Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALOX12 | P18054 | 3/20 | 0.58 |
| ▸ | CYP19A1 | P11511 | 12/20 | 0.44 |
| ▸ | ALOX15 | P16050 | 2/20 | 0.43 |
| ▸ | TYR | P14679 | 1/20 | 0.38 |
| ▸ | PSMB5 | P28074 | 1/20 | 0.36 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.35 |
| ▸ | TRPV1 | Q8NER1 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL20826751 | 1.00 | ALOX12 (0.58) | ALOX12CYP19A1ALOX15TYRPSMB5 | |
| SCHEMBL20826766 | 1.00 | ALOX12 (0.58) | ALOX12CYP19A1ALOX15TYRPSMB5 | |
| SCHEMBL17938825 | 0.87 | ALOX12 (0.62) | ALOX12CYP19A1ALOX15TYRPSMB5 | |
| SCHEMBL21845202 | 0.83 | ALOX12 (0.58) | ALOX12CYP19A1ALOX15TYRPSMB5 | |
| SCHEMBL329826 | 0.83 | ALOX12 (0.58) | ALOX12CYP19A1ALOX15TYRKCNH2 | |
| SCHEMBL19472344 | 0.76 | CYP19A1 (0.56) | ALOX12CYP19A1ALOX15TYRPSMB5 | |
| SCHEMBL5797926 | 0.75 | ALOX12 (0.75) | ALOX12CYP19A1ALOX15KCNH2TRPV1 | |
| SCHEMBL16152440 | 0.75 | ALOX12 (0.75) | ALOX12CYP19A1ALOX15KCNH2TRPV1 | |
| SCHEMBL131543 | 0.75 | ALOX12 (0.75) | ALOX12CYP19A1ALOX15KCNH2TRPV1 | |
| SCHEMBL572236 | 0.74 | ALOX12 (1.00) | ALOX12CYP19A1ALOX15 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 14 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2020051644-A1 | TREATMENT OF PERIPHERAL NERVOUS TISSUE INFLAMMATION | NORBIO NO. 2 PTY LTD (AU) | 2020-03-19 | — | — | WO | disclosed |
| WO-2019051548-A1 | TREATMENT OF NEURO-INFLAMMATION | NORBIO NO. 2 PTY LTD (AU) | 2019-03-21 | — | — | WO | disclosed |
| EP-2526941-A1 | Anti-inflammatory Modalities | Marshall Edwards, Inc. (US) | 2012-11-28 | — | — | EP | disclosed |
| EP-2526941-A1 | Anti-inflammatory Modalities | Marshall Edwards, Inc. (US) | 2012-11-28 | — | — | EP | disclosed |
| US-20120059176-A1 | ANTI-INFLAMMATORY MODALITIES | MARSHALL EDWARDS, INC. (US) | 2012-03-08 | — | — | US | disclosed |
| US-20120059176-A1 | ANTI-INFLAMMATORY MODALITIES | MARSHALL EDWARDS, INC. (US) | 2012-03-08 | — | — | US | disclosed |
| US-20120059176-A1 | ANTI-INFLAMMATORY MODALITIES | MARSHALL EDWARDS, INC. (US) | 2012-03-08 | — | — | US | disclosed |
| CN-101203219-B | Anti-inflammatory modalities | NOVOGEN RES PTY LTD | 2011-06-15 | — | — | CN | disclosed |
| US-20090131513-A1 | ANTI-INFLAMMATORY MODALITIES | NOVOGEN RESEARCH PTY LTD. (AU) | 2009-05-21 | — | — | US | disclosed |
| US-20090131513-A1 | ANTI-INFLAMMATORY MODALITIES | NOVOGEN RESEARCH PTY LTD. (AU) | 2009-05-21 | — | — | US | disclosed |
| US-20090131513-A1 | ANTI-INFLAMMATORY MODALITIES | NOVOGEN RESEARCH PTY LTD. (AU) | 2009-05-21 | — | — | US | disclosed |
| CN-101203219-A | Anti-inflammatory modalities | NOVOGEN RES PTY LTD (AU) | 2008-06-18 | — | — | CN | disclosed |
| EP-1861090-A1 | ANTI-INFLAMMATORY MODALITIES | Novogen Research Pty. Ltd. (AU) | 2007-12-05 | — | — | EP | disclosed |
| WO-2006108212-A1 | ANTI-INFLAMMATORY MODALITIES | NOVOGEN RESEARCH PTY LTD (AU) | 2006-10-19 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120059176-A1 | ANTI-INFLAMMATORY MODALITIES | TNF, PTGES, NFKBIA | ALOX12 61/4885CYP19A1 463/4885ALOX15 72/4885 |
| US-20090131513-A1 | ANTI-INFLAMMATORY MODALITIES | TNF, PTGES, NFKBIA | ALOX12 61/4885CYP19A1 463/4885ALOX15 72/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.